Latest Breaking News On - Stravitz sanyal institute for liver disease metabolic health - Page 1 : comparemela.com

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Met primary and Hepatic Encephalopathy endpoints in Phase 2 studyIncrease in Skeletal Muscle Index observed at Week 24 was maintained through 52 weeksParticipants on placebo increased SMI when.

Lipocine (LPCN) Reports Positive Week 52 Results from LPCN 1148 Phase 2 Study

Oral androgen receptor agonist improves sarcopenia, encephalopathy in cirrhosis

Retatrutide 12 mg resolved steatosis in more than 90% of patients with obesity, MASLD

HistoIndex embarks on partnership with VCU's Stravitz-Sanyal Institute for Liver Disease and Metabolic Health in the study of liver diseases

Advancing ML/AI-based technology in the study of liver diseases by furthering strategic partnerships using a stain-free digital pathology system.S.